Nanomedicine in Cancer Immunotherapy

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.

1. Immunoadjuvants for cancer immunotherapy
2. Nanotechnology as an emerging option in cancer immunotherapy
3. Different administration routes for nanovectors in cancer immunotherapy
4. Two-dimensional materialbased nanomedicines for cancer immunotherapy
5. Hydrogel-based nanomedicines for cancer immunotherapy
6. Exosomes-based nanomedicines for cancer immunotherapy
7. Lipid-based nanomedicines for cancer immunotherapy
8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy
9. Liposome-based nanomedicines for cancer immunotherapy
10. Biomembrane-based nanoparticles for cancer immunotherapy
11. Dendrimer-based nanomedicines for cancer immunotherapy
12. Magnetic nanocarriers for cancer immunotherapy
13. Inhaled delivery of immunotherapy for treatment of lung cancer
14. Nano-based vaccination and their administration routes in cancer immunotherapy
15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy